StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Atripla (efavirenz / FTC / TDF by Quarter

Atripla (efavirenz / FTC / TDF — legacy breakout) — Europe sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Atripla (efavirenz / FTC / TDF: $2M in Q4 2021, down 50.0% from a year earlier. That is the lowest of the 21 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2021
2
Period ended Dec 31, 2021
Change on a year earlier
-50.0%
4 in Q4 2020
History
21 quarters
Since Q4 2016
Sources
14
Documents cited below

Where the Q4 2021 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2022-02-23) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAtripla (efavirenz / FTC / TDF — legacy breakout) — Europe sales ($M) ($M)Year on yearSource
Q4 2021Dec 31, 20212-50.0%Form 10-K (filed 2022-02-23) ↗
Q3 2021Sep 30, 20212-60.0%Form 10-Q (filed 2021-11-03) ↗
Q2 2021Jun 30, 20214-20.0%Form 10-Q (filed 2021-08-05) ↗
Q1 2021Mar 31, 20214-42.9%Form 10-Q (filed 2021-05-06) ↗
Q4 2020Dec 31, 20204-50.0%Form 10-K (filed 2022-02-23) ↗
Q3 2020Sep 30, 20205-50.0%Form 10-Q (filed 2021-11-03) ↗
Q2 2020Jun 30, 20205-80.8%Form 10-Q (filed 2021-08-05) ↗
Q1 2020Mar 31, 20207-56.2%Form 10-Q (filed 2020-05-06) ↗
Q4 2019Dec 31, 20198-33.3%Form 10-K (filed 2022-02-23) ↗
Q3 2019Sep 30, 201910-65.5%Form 10-Q (filed 2019-11-05) ↗
Q2 2019Jun 30, 201926-33.3%Form 10-Q (filed 2019-08-06) ↗
Q1 2019Mar 31, 201916-68.6%Form 10-Q (filed 2020-05-06) ↗
Q4 2018Dec 31, 201812-84.2%Form 10-K (filed 2021-02-25) ↗
Q3 2018Sep 30, 201829-63.3%Form 10-Q (filed 2019-11-05) ↗
Q2 2018Jun 30, 201839-54.7%Form 10-Q (filed 2019-08-06) ↗
Q1 2018Mar 31, 201851-45.7%Form 10-Q (filed 2019-05-08) ↗

Cite this data

StockData. (2026). Gilead Sciences Atripla (efavirenz / FTC / TDF ($M), quarterly Q4 2016–Q4 2021 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-atripla-eu

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.